Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2011 Nov 11

PMID 22072940

Citations 24

Authors

In-Sung Song

Hyoung-Kyu Kim

Seung-Hun Jeong

Sung-Ryul Lee

Nari Kim

Byoung Doo Rhee

Kyung Soo Ko

Jin Han

Affiliations

Soon will be listed here.

Abstract

Mitochondria are involved either directly or indirectly in oncogenesis and the alteration of metabolism in cancer cells. Cancer cells contain large numbers of abnormal mitochondria and produce large amounts of reactive oxygen species (ROS). Oxidative stress is caused by an imbalance between the production of ROS and the antioxidant capacity of the cell. Several cancer therapies, such as chemotherapeutic drugs and radiation, disrupt mitochondrial homeostasis and release cytochrome c, leading to apoptosome formation, which activates the intrinsic pathway. This is modulated by the extent of mitochondrial oxidative stress. The peroxiredoxin (Prx) system is a cellular defense system against oxidative stress, and mitochondria in cancer cells are known to contain high levels of Prx III. Here, we review accumulating evidence suggesting that mitochondrial oxidative stress is involved in cancer, and discuss the role of the mitochondrial Prx III antioxidant system as a potential target for cancer therapy. We hope that this review will provide the basis for new strategic approaches in the development of effective cancer treatments.

Citing Articles

Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma.

Shen Y, Xu H, Li L, Lu Y, Zhang M, Huang X Cancer Manag Res. 2021; 13:5725-5737.

PMID: 34290530 PMC: 8289334. DOI: 10.2147/CMAR.S319048.

MicroRNA-383 promotes reactive oxygen species-induced autophagy via downregulating peroxiredoxin 3 in human glioma U87 cells.

Xu Z, Zeng X, Li M, Liao J, Chen Q Exp Ther Med. 2021; 21(5):439.

PMID: 33747176 PMC: 7967820. DOI: 10.3892/etm.2021.9870.

Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma.

Xing X, Yuan H, Liu H, Tan X, Zhao B, Wang Y Genomics Proteomics Bioinformatics. 2021; 19(1):94-107.

PMID: 33662630 PMC: 8498920. DOI: 10.1016/j.gpb.2020.09.005.

Skeletal muscle proteome of piglets is affected in a muscle-dependent manner by a limiting total sulfur amino acid supply.

Conde-Aguilera J, Lefaucheur L, Gondret F, Delgado-Andrade C, Mercier Y, Tesseraud S Eur J Nutr. 2019; 59(7):2939-2951.

PMID: 31707545 DOI: 10.1007/s00394-019-02133-y.

Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.

Ismail T, Kim Y, Lee H, Lee D, Lee H Int J Mol Sci. 2019; 20(18).

PMID: 31500275 PMC: 6770548. DOI: 10.3390/ijms20184407.

References

Huang P, Feng L, Oldham E, Keating M, Plunkett W . Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000; 407(6802):390-5. DOI: 10.1038/35030140. View

Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K . Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000; 156(1):27-35. DOI: 10.1016/s0304-3835(00)00434-1. View

Power J, Shannon J, Blumbergs P, Gai W . Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. Am J Pathol. 2002; 161(3):885-94. PMC: 1867235. DOI: 10.1016/S0002-9440(10)64249-6. View

Manta B, Hugo M, Ortiz C, Ferrer-Sueta G, Trujillo M, Denicola A . The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2. Arch Biochem Biophys. 2008; 484(2):146-54. DOI: 10.1016/j.abb.2008.11.017. View

Kropotov A, Gogvadze V, Shupliakov O, Tomilin N, Serikov V, Tomilin N . Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res. 2006; 312(15):2806-15. DOI: 10.1016/j.yexcr.2006.05.006. View

Woo H, Kang S, Kim H, Yang K, Chae H, Rhee S . Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J Biol Chem. 2003; 278(48):47361-4. DOI: 10.1074/jbc.C300428200. View

Kim S, Fountoulakis M, Cairns N, Lubec G . Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl. 2002; (61):223-35. DOI: 10.1007/978-3-7091-6262-0_18. View

Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J . Cloning and expression of a novel mammalian thioredoxin. J Biol Chem. 1997; 272(5):2936-41. DOI: 10.1074/jbc.272.5.2936. View

Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow H . Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol. 2007; 25(13):1779-84. DOI: 10.1200/JCO.2006.08.9672. View

10.

Lehtonen S, Svensk A, Soini Y, Paakko P, Hirvikoski P, Kang S . Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004; 111(4):514-21. DOI: 10.1002/ijc.20294. View

11.

Juarez J, Manuia M, Burnett M, Betancourt O, Boivin B, Shaw D . Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci U S A. 2008; 105(20):7147-52. PMC: 2438219. DOI: 10.1073/pnas.0709451105. View

12.

Knoops B, Clippe A, Bogard C, Arsalane K, Wattiez R, Hermans C . Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J Biol Chem. 1999; 274(43):30451-8. DOI: 10.1074/jbc.274.43.30451. View

13.

Guzman M, Rossi R, Neelakantan S, Li X, Corbett C, Hassane D . An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007; 110(13):4427-35. PMC: 2234793. DOI: 10.1182/blood-2007-05-090621. View

14.

Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87(1):99-163. DOI: 10.1152/physrev.00013.2006. View

15.

Rhee S, Chae H, Kim K . Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38(12):1543-52. DOI: 10.1016/j.freeradbiomed.2005.02.026. View

16.

Panfili E, Sandri G, Ernster L . Distribution of glutathione peroxidases and glutathione reductase in rat brain mitochondria. FEBS Lett. 1991; 290(1-2):35-7. DOI: 10.1016/0014-5793(91)81219-x. View

17.

Bey E, Bentle M, Reinicke K, Dong Y, Yang C, Girard L . An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A. 2007; 104(28):11832-7. PMC: 1913860. DOI: 10.1073/pnas.0702176104. View

18.

Galluzzi L, Kroemer G . Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008; 135(7):1161-3. DOI: 10.1016/j.cell.2008.12.004. View

19.

Rajkumar S, Richardson P, Lacy M, Dispenzieri A, Greipp P, Witzig T . Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007; 13(20):6162-7. DOI: 10.1158/1078-0432.CCR-07-0807. View

20.

Chae H, Kim H, Kang S, Rhee S . Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract. 1999; 45(2-3):101-12. DOI: 10.1016/s0168-8227(99)00037-6. View